Treatment of metastatic brain tumor by administration of antibody-drug conjugate
A technology for brain tumors and metastases, applied in drug combinations, anti-tumor drugs, anti-animal/human immunoglobulins, etc., can solve problems such as unestablished standard therapies
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0511] Example 1: Production of Antibody-Drug Conjugates
[0512] A humanized anti-HER2 antibody (an antibody comprising a heavy chain consisting of amino acid residues 1-449 of SEQ ID NO: 1 and a light chain) was used according to the production method described in International Publication No. WO 2015 / 115091 The light chain consists of the amino acid sequence consisting of amino acid residues 1-214 of SEQ ID NO: 2) to produce an antibody-drug conjugate in which the drug-linker represented by the formula is passed through Conjugation of thioether bond to anti-HER2 antibody (hereinafter, referred to as "antibody-drug conjugate (1)"):
[0513] [Formula 22]
[0514]
[0515] Where A represents the linking position with the antibody. The DAR of antibody-drug conjugate (1) was 7.8.
Embodiment 2
[0516] Example 2: Life extension test
[0517] Mice: Experiments were performed on 5-6-week-old female BALB / c nude mice (Charles River Laboratories Japan, Inc.).
[0518] Antibody-drug conjugate (1) was diluted with ABS buffer (10 mM acetate buffer (pH 5.5), 5% sorbitol) and administered intravenously at a solution volume of 10 mL / kg into the tail vein .
[0519] KPL-4-Luc, in which the luciferase gene was transfected into KPL-4 cells, was used by Dr. Junichi Kurebayashi from Kawasaki Medical School (British Journal of Cancer, (1999) 79 (5 / 6).707-717) A human breast cancer line was obtained. Suspend KPL-4-Luc in saline, add 1 x 10 4 Cells were transplanted intracranially into female nude mice, and the mice were randomized 7 days after transplantation (day 0). Antibody-drug conjugate (1 ) was administered intravenously at a dose of 10 mg / kg into the tail vein on days 0 and 21. The solvent was administered to the control group. The number of mice in each group was 5 and th...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


